This inventor holds 2 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: University of California. Active years: 2021-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Oakland, CA (US) (2021)
- Santa Monica, CA (US) (2023)
Company Filing History:
Years Active: 2021-2023
Title: Christopher S Seet: Innovator in Immunotherapy
Introduction
Christopher S Seet is a prominent inventor based in Santa Monica, CA (US). He has made significant contributions to the field of immunotherapy, holding 2 patents that focus on innovative methods for generating human dendritic cells and T-cells from stem cells. His work is pivotal in advancing therapeutic techniques that can enhance immune responses against diseases.
Latest Patents
Christopher's latest patents include a method for generating human dendritic cells for immunotherapy. This patent outlines various embodiments for producing a cell population enriched for CLEC9A+ dendritic cells. The methods involve culturing stem cells and/or progenitor cells in a specialized culture medium that includes a notch ligand, stem cell factor (SCF), FLT3 ligand (FLT3L), thrombopoietin (TPO), and IL-3 and/or GMCSF. Additionally, he has developed methods for generating T-cells from stem cells, which include therapeutic methods using engineered T-cells. These methods involve preparing three-dimensional cell culture compositions that comprise stroma cells and hematopoietic stem or progenitor cells in a serum-free medium for producing T-cells.
Career Highlights
Christopher S Seet is affiliated with the University of California, where he continues to push the boundaries of research in immunotherapy. His innovative approaches have the potential to revolutionize treatment options for various diseases, particularly in enhancing the body's immune response.
Collaborations
Some of his notable coworkers include Gay M Crooks and Amélie Montel-Hagen, who collaborate with him on various research projects aimed at improving immunotherapeutic techniques.
Conclusion
Christopher S Seet is a key figure in the field of immunotherapy, with his patents reflecting groundbreaking advancements in the generation of dendritic cells and T-cells. His work at the University of California continues to inspire new therapeutic approaches that could significantly impact patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile